Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Regulatory Compliance Consulting in 2026: FDA, EMA, and Regulatory Affairs

Discover how pharmaceutical regulatory consulting helps organizations eliminate common GMP compliance gaps, improve FDA Compliance and EMA Compliance, implement ICH Guidelines, strengthen regulatory strategy, and achieve greater inspection readiness for successful global market authorization.
  • Blog, Quality Management System
Infographic illustrating common GMP inspection gaps, including documentation, CAPA, data integrity, change control, and risk management that support regulatory consulting services, FDA Compliance, EMA Compliance, and ICH Guidelines.

Pharma Consultancy Services in 2026: GMP, Validation, Regulatory, and Quality Systems

Modern pharmaceutical companies rely on expert consulting to strengthen GMP compliance, validation, regulatory readiness, and quality systems. This guide explores the core consulting disciplines, practical selection criteria, and proven strategies that drive operational excellence throughout the pharmaceutical product lifecycle.
  • Blog, Quality Management System
Pharmaceutical consulting company supporting GMP consulting, Validation consulting, Regulatory Affairs consulting, and Pharmaceutical Quality Assurance across the product lifecycle.

AI Is Accelerating Drug Development; But Data Risks Could Break It

BioSpace’s NextGen 2026 biotech leaders highlighted at a recent industry discussion how artificial intelligence is rapidly reshaping drug development while exposing a critical weakness in pharmaceutical innovation: data quality. Executives from emerging biotech companies emphasized that while AI accelerates discovery
  • News
AI Is Accelerating Drug Development; But Data Risks Could Break It

Hidden GMP Failure Detected in Inspection — Drug Approval Halted

A planned expansion of Regeneron’s flagship Eylea HD product has been rejected by the US FDA after a key fill-finish manufacturing site failed to meet GMP inspection standards, triggering a full regulatory setback and delaying a major lifecycle upgrade.
  • News
Hidden GMP Failure Detected in Inspection — Drug Approval Halted